Sith Sathornsumetee

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.

John Sampson, Allan H Friedman, A. Friedman, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeting multiple kinases in glioblastoma multiforme

D. Reardon, S. Sathornsumetee, Sith Sathornsumetee, 2009 .

Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma

Darell D. Bigner, Allan H. Friedman, Jeremy N. Rich, 2007, Clinical Cancer Research.

Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan.

Yiting Cao, Mark W Dewhirst, M. Dewhirst, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor.

Qiulian Wu, R. McLendon, D. Bigner, 2006, Cancer research.

Molecularly targeted therapy for malignant glioma

D. Reardon, A. Desjardins, J. Vredenburgh, 2007, Cancer.

Twisted tango: brain tumor neurovascular interactions

J. Rich, A. Hjelmeland, J. Lathia, 2011, Nature Neuroscience.

Malignant glioma drug discovery – targeting protein kinases

J. Rich, S. Sathornsumetee, Jeremy N Rich, 2007, Expert opinion on drug discovery.

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme.

Allan H Friedman, James M Provenzale, R. McLendon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Hui Wang, Yiting Cao, Christine Eyler, 2009, Cancer cell.

Targeting multiple kinases in glioblastoma multiforme.

D. Reardon, S. Sathornsumetee, David A Reardon, 2009, Expert opinion on investigational drugs.

Diagnosis and treatment of high-grade astrocytoma.

D. Reardon, J. Rich, S. Sathornsumetee, 2007, Neurologic clinics.